STAT+: FDA’s Califf says congressional report on Aduhelm controversy contained “no surprises”
FDA head Robert Califf made his first public comments following a congressional investigation into the agency’s role in approving Aduhelm.
News
STAT+: PACT Pharma’s personalized cancer treatments, powered by CRISPR, clear early safety hurdles
PACT Pharma and UCLA researchers infused individualized cocktails of CRISPR-edited immune cells into 16 cancer patients with minimal and manageable side effects. […]
News
STAT+: After blazing trails in RNA-targeted drugs, Ionis jumps into gene editing
Ionis Pharmaceuticals — which blazed a trail in RNA-targeted medicines — is jumping into gene editing with a new partnership with Metagenomi. […]
News
STAT+: Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments
Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments. […]
